NasdaqGS:ICPT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. More Details


Snowflake Analysis

Slightly overvalued with limited growth.

Share Price & News

How has Intercept Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ICPT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.3%

ICPT

-1.0%

US Biotechs

-3.1%

US Market


1 Year Return

-39.2%

ICPT

31.3%

US Biotechs

12.7%

US Market

Return vs Industry: ICPT underperformed the US Biotechs industry which returned 31.3% over the past year.

Return vs Market: ICPT underperformed the US Market which returned 12.7% over the past year.


Shareholder returns

ICPTIndustryMarket
7 Day-10.3%-1.0%-3.1%
30 Day-18.1%-0.5%-2.9%
90 Day-50.2%-2.2%8.2%
1 Year-39.2%-39.2%33.6%31.3%15.3%12.7%
3 Year-30.5%-30.5%17.6%11.9%37.8%28.5%
5 Year-76.1%-76.1%27.2%18.2%90.9%69.4%

Price Volatility Vs. Market

How volatile is Intercept Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Intercept Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ICPT ($39.65) is trading below our estimate of fair value ($127.32)

Significantly Below Fair Value: ICPT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ICPT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ICPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ICPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ICPT has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is Intercept Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?

51.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICPT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ICPT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ICPT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ICPT's revenue (30.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: ICPT's revenue (30.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ICPT is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Intercept Pharmaceuticals performed over the past 5 years?

-5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ICPT is currently unprofitable.

Growing Profit Margin: ICPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ICPT is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare ICPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: ICPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Intercept Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ICPT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ICPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ICPT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ICPT has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 11.8% each year.


Next Steps

Dividend

What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ICPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ICPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Mark Pruzanski (52 yo)

18.67yrs

Tenure

US$6,615,785

Compensation

Dr. Mark Pruzanski, M.D., founded Intercept Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer and President since 2002. Dr. Pruzanski serves as the President and Chief Executive Office ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD6.62M) is above average for companies of similar size in the US market ($USD4.64M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Pruzanski
Founder18.67yrsUS$6.62m1.7%
$ 22.2m
Sandip Kapadia
CFO, Treasurer & Principal Accounting Officer4.17yrsUS$2.33m0.054%
$ 700.0k
Jerome Durso
Chief Operating Officer3.58yrsUS$4.28m0.058%
$ 753.1k
Ryan Sullivan
General Counsel & Secretary2.58yrsUS$3.08m0.044%
$ 580.9k
Richard Kim
President of U.S. Commercial & Strategic Marketing5.17yrsUS$2.40m0.032%
$ 415.3k
Lisa DeFrancesco
Vice President of Investor Relations1yrno datano data
David Ford
Chief Human Resources Officer3.33yrsUS$1.91m0.017%
$ 216.9k
Lisa Morrison
President of International4.17yrsUS$1.93m0.045%
$ 584.3k
Christian Weyer
Executive Vice President of Research & Development2.83yrsno data0.023%
$ 303.0k
Gail Cawkwell
Senior Vice President of Medical Affairs2.58yrsUS$2.21m0.026%
$ 345.2k
Jason Campagna
Chief Medical Officer0.75yrno data0.026%
$ 345.4k
Justine O'Malley
Vice President of Corporate Affairs3yrsno datano data

3.2yrs

Average Tenure

51yo

Average Age

Experienced Management: ICPT's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Pruzanski
Founder18.67yrsUS$6.62m1.7%
$ 22.2m
Daniel Bradbury
Independent Director4.17yrsUS$326.36k0.045%
$ 594.7k
Glenn Sblendorio
Independent Director6.58yrsUS$331.36k0.021%
$ 281.0k
Daniel Welch
Independent Director4.83yrsUS$328.86k0.020%
$ 256.3k
Luca Benatti
Independent Director6.17yrsUS$326.36k0.028%
$ 363.4k
Srinivas Akkaraju
Independent Director7.92yrsUS$316.36k0.065%
$ 853.5k
Gino Santini
Lead Independent Director2.58yrsUS$336.36k0.022%
$ 288.9k
Paolo Fundaro
Independent Chairman of the Board4.92yrsUS$341.36k0.059%
$ 770.5k
Alan Hofmann
Member of the Scientific Advisory Boardno datano datano data
Scott Friedman
Member of the Scientific Advisory Boardno datano datano data
Massimo Pinzani
Member of the Scientific Advisory Boardno datano datano data
Aldo Roda
Member of the Scientific Advisory Boardno datano datano data

5.5yrs

Average Tenure

59yo

Average Age

Experienced Board: ICPT's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ICPT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Intercept Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intercept Pharmaceuticals, Inc.
  • Ticker: ICPT
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.308b
  • Shares outstanding: 32.98m
  • Website: https://www.interceptpharma.com

Number of Employees


Location

  • Intercept Pharmaceuticals, Inc.
  • 10 Hudson Yards
  • 37th floor
  • New York
  • New York
  • 10001
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ICPTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2012
I4PDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2012
ICPT *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNOct 2012

Biography

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 05:42
End of Day Share Price2020/09/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.